The safety and feasibility of intratumoral injection of another adenoviral vector encoding HSV-TK (Ad.TK) in advanced hepatocellular carcinoma (HCC) was evaluated in a phase I trial [NCT00844623]. Here, TKT is linked to hepatocellular carcinoma.